The North Staffordshire Joint Formulary (NSJF) has been developed jointly between North Staffordshire CCG, Stoke-on-Trent CCG, University Hospital of North Staffordshire NHS Trust and North Staffordshire Combined Healthcare NHS Trust. It is applicable to all prescribers working within primary care or hospitals across North Staffordshire and Stoke-on-Trent.
The main aim of the Joint Formulary is to promote safe, effective and economic prescribing in both general practice and hospital. Use of the Joint Formulary will also help to ensure seamless prescribing for patients between Primary and Secondary Care, thereby reducing the confusion and possible errors that can happen when medications are changed.
For more information about Joint Formulary, please see the pdf Formulary Introduction 2018 (359 KB)
Joint Formulary Documents
Information and recommendations presented have been produced following consultation with local specialists and primary care colleagues and with others who have a particular interest and/or knowledge in specific areas of therapeutics.
Each section of the Joint Formulary has been approved by the North Staffordshire and Stoke-on-Trent Area Prescribing Committee. The Joint Formulary is an evolving and dynamic document and it is regularly reviewed and updated.
This document contains information related to; Dysepsia and Gastro-Oesophageal Reflux Disease and more.
This document contains information related to; Positive Inotropic Agents, Diuretics and more.
This document contains information related to; Bronchodilators, Corticosteroids and more.
This document contains information related to; Hypnotics and Anxiolytics, Drugs used in psychoses and related disorders and more.
This document contains information related to; Antibacterial drugs, Antifungal drugs, Antiviral drugs, Antiprotozoal drugs and Anthelmintics.
This document contains information related to; Drugs used in diabetes, thyroid and antithyroid drugs and more.
This document contains information related to; Drugs used in obstetrics, treatment of vaginal and vulval conditions, contraceptives and drugs for genito-urinary disorders.
This document contains information related to; Cytotoxic drugs, drugs affecting the immune response and sex hormones and hormone antagonists in malignant disease.
This document contains information related to; Anaemias and some other blood disorders, fluids and electrolytes and more.
This document contains information related to; Drugs used in rheumatic diseases and gout, drugs used in neuromuscular disorders and drugs for the treatment of soft-tissue disorders and topical pain relief.
This document contains information related to; Anti-infective eye preperations and more.
This document contains information related to; Drugs acting on the ear, nose and oropharynx.
This document contains information related to; Emollient and barrier preparations, topical anaesthetics and antipruritics, topical corticosteroids and more.
Additional Guidance Documents
The aim of this formulary is to identify the most appropriate use of catheters, sheaths, drainage bags and associated appliances for use in the community. It is expected that the majority of patients can be managed with the products recommended. This formulary provides guidance to prescribers for appropriate product choices for the majority of patients and is not intended to restrict patient choice.
In 2010 The Department of Health instructed the National Prescribing Centre (NPC) to produce guidance on the purchasing and prescribing of dressings. An expert focus group was established which looked into ensuring quality and productivity for patient care. The guiding principles considered the whole patient care pathway, rather than focusing solely on the products being prescribed.
With this guidance Staffordshire and Stoke on Trent Partnership Trust (SSOTP) Tissue Viability Service (TVS) have developed a robust, evidenced based and concise Wound Care Formulary.
The formulary is designed to support nurses in their decision making process in the area of wound care. The formulary will be subject to review and a mechanism for comments and the assessment of new products will be ongoing. Any products which are identified as like for like, after going through a robust evaluation process and agreed with respective partners will be changed over if cost savings can be identified.
Drugs for the management of restlessness, nausea, vomiting, respiratory tract secretions and pain. (Jan 2013)
Antimicrobial Guidelines 2016
The 2016 version supersedes any previous edition of the antimicrobial prescribing guidelines that were last issued in 2014. All previous copies of the guidelines either orange, red or blue booklets should no longer be used.